Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Google Scholar citation report
Citations : 3330
Journal of Biotechnology & Biomaterials received 3330 citations as per Google Scholar report
Indexed In
- Index Copernicus
- Google Scholar
- Sherpa Romeo
- Open J Gate
- Genamics JournalSeek
- Academic Keys
- ResearchBible
- China National Knowledge Infrastructure (CNKI)
- Access to Global Online Research in Agriculture (AGORA)
- Electronic Journals Library
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- SWB online catalog
- Virtual Library of Biology (vifabio)
- Publons
- Geneva Foundation for Medical Education and Research
- Euro Pub
- ICMJE
Useful Links
Recommended Journals
Related Subjects
Share This Page
In Association with
Aldehyde dehydrogenases as target for biomarker and drug discovery
Joint Event on 22nd Global Congress on Biotechnology & 5th International Conference on Enzymology and Protein Chemistry
Klaus Pors
University of Bradford, UK
ScientificTracks Abstracts: J Biotechnol Biomater
Abstract
The human aldehyde dehydrogenases (ALDHs) play a major role in detoxifying highly reactive aldehydes into carboxylic acids. Deregulation of ALDHs have implications in a number of cancers. They play an important role as a cancer stem cell (CSC) marker due to high activity found in CSCs while high expression is also known to lead to resistance to chemotherapeutic drugs. Although the exact role of ALDH is not fully understood, emerging information indicates several isoforms from the ALDH1 family, ALDH3A1 and ALDH7A1 play key roles in many cancer types. To probe the role of ALDH functional activity, at this meeting we will present new data on small molecules that inhibits ALDH functional activity using cell free and cellbased assays; diethylbenzaldehyde (DEAB) was used as a control for inhibition while Aldefluor assay was used as an assay to demonstrate functional activity. Furthermore, our investigations in prostate cancer revealed that several ALDH-affinic probe compounds were able to reduce cell viability in both drug-resistant PC3 prostate cancer cells and patient-derived samples while synergistic effect was observed in combination treatment with docetaxel. Our early drug discovery approach will be presented at the meeting and include drug design to target ALDH7A1, an enzyme that is linked with oxidative stress, lysine metabolism and several diseases including cancer.Biography
Klaus Pors is an Associate Professor of Chemical Biology at The Institute of Cancer Therapeutics, University of Bradford, UK. His research group is involved with discovery of novel biological and chemical tools to explore the importance of enzymes in different disease states. Particular focus is on exploiting abnormal cytochrome P450 (CYP), aldehyde dehydrogenase (ALDH) or aldo-keto reductase (AKR) expression in the tumour microenvironment as target for biomarker and drug discovery; he has published 35 papers on these topics. He is a RSC Chemical Biology and Bioorganic Group committee member and the European Editor of Journal of Cancer Metastasis and Treatment.
E-mail: k.pors1@bradford.ac.uk
